MedPath

Cyclophosphamide

Generic Name
Cyclophosphamide
Brand Names
Procytox
Drug Type
Small Molecule
Chemical Formula
C7H15Cl2N2O2P
CAS Number
50-18-0
Unique Ingredient Identifier
6UXW23996M
Background

Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication

Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
Associated Therapies
-
Clinical Trials
Related News

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer

Phase 1
Withdrawn
Conditions
Leukemia
Myelodysplastic Syndromes
Lymphoma
First Posted Date
2004-02-16
Last Posted Date
2020-07-31
Lead Sponsor
Jonsson Comprehensive Cancer Center
Registration Number
NCT00004114

Chemotherapy, Filgrastim and Peripheral Stem Cell Transplantation in Patients With Chronic Myelogenous Leukemia

Phase 2
Terminated
Conditions
Leukemia
First Posted Date
2004-02-12
Last Posted Date
2017-11-29
Lead Sponsor
Masonic Cancer Center, University of Minnesota
Registration Number
NCT00005986
Locations
🇺🇸

University of Minnesota Cancer Center, Minneapolis, Minnesota, United States

Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast Cancer

Phase 1
Withdrawn
Conditions
Breast Cancer
First Posted Date
2004-02-12
Last Posted Date
2018-05-16
Lead Sponsor
Beth Israel Deaconess Medical Center
Registration Number
NCT00006123
Locations
🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

🇺🇸

Hackensack University Medical Center, Hackensack, New Jersey, United States

Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma

First Posted Date
2004-02-11
Last Posted Date
2024-11-04
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
65
Registration Number
NCT00077285
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome

Phase 2
Completed
Conditions
Leukemia
Myelodysplastic Syndromes
First Posted Date
2004-02-11
Last Posted Date
2012-07-16
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
31
Registration Number
NCT00077116
Locations
🇨🇭

Universitaetsspital-Basel, Basel, Switzerland

🇧🇪

AZ Sint-Jan, Brugge, Belgium

🇧🇪

H. Hartziekenhuis - Roeselaere., Roeselare, Belgium

and more 6 locations

Biological Therapy in Treating Patients With Glioblastoma Multiforme

Phase 2
Completed
Conditions
Brain and Central Nervous System Tumors
First Posted Date
2004-02-09
Last Posted Date
2013-12-04
Lead Sponsor
The Cleveland Clinic
Target Recruit Count
40
Registration Number
NCT00003185
Locations
🇺🇸

Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States

Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer

Phase 1
Terminated
Conditions
Breast Cancer
First Posted Date
2004-02-09
Last Posted Date
2020-07-14
Lead Sponsor
Louisiana State University Health Sciences Center Shreveport
Target Recruit Count
12
Registration Number
NCT00003086
Locations
🇺🇸

Louisiana State University School of Medicine, Shreveport, Louisiana, United States

Adjuvant High-Dose, Sequential Chemotherapy in Treating Patients With Resected Breast Cancer

Phase 2
Completed
Conditions
Breast Cancer
First Posted Date
2004-02-06
Last Posted Date
2009-08-26
Lead Sponsor
Yale University
Target Recruit Count
89
Registration Number
NCT00002679
Locations
🇺🇸

Yale Comprehensive Cancer Center, New Haven, Connecticut, United States

Combination Chemotherapy Before Surgery in Treating Women With Breast Cancer

Phase 1
Completed
Conditions
Breast Cancer
First Posted Date
2004-02-03
Last Posted Date
2012-07-18
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
15
Registration Number
NCT00008034
Locations
🇨🇭

Hopital Cantonal Universitaire de Geneva, Geneva, Switzerland

Trastuzumab and Chemotherapy Followed by Surgery and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer

Phase 1
Completed
Conditions
Breast Cancer
First Posted Date
2004-02-03
Last Posted Date
2011-03-28
Lead Sponsor
NYU Langone Health
Registration Number
NCT00009997
Locations
🇺🇸

NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy